[This entry is marked for removal.]

GE Medical Systems and Amersham announced in April 2004 the completion of a share exchange acquisition of Amersham Health by GE. The result of this acquisition is the new GE Healthcare, based in the UK, totally owned by General Electric (GE).

Amersham Health, was the imaging diagnostics and therapy business of Amersham plc.

The rapid improvements in instrumentation, which have added benefit to the use of extracellular fluid agents such as Omniscan™, have also diminished the market potential for blood pool products such as Clariscan™. As a consequence, Amersham decided to discontinue the development of Clariscan™.

[This entry is marked for removal.]

GE Medical Systems and Amersham announced in April 2004 the completion of a share exchange acquisition of Amersham Health by GE. The result of this acquisition is the new GE Healthcare, based in the UK, totally owned by General Electric (GE).

Amersham plc, was a producer of contrast imaging agents used to enhance image quality in X-ray, magnetic resonance imaging, and ultrasound procedures. It was also a leading producer of radiopharmaceuticals used in nuclear medicine imaging. Amersham Health was the firm's imaging, diagnostics, and therapeutics segment. Amersham plc was involved in biotechnology research through its Amersham Biosciences unit, which made scanners, sequencers, microarrays, industrial separations, and other research supplies.

[This entry is marked for removal.]

(July 20, 2009 - EPIX Pharmaceuticals, Inc. announced today that, in light of the company's lack of capital and inability to obtain additional financing or consummate a strategic transaction, it has entered into an Assignment for the Benefit of Creditors, effective immediately, in accordance with Massachusetts law).
EPIX has been a specialty pharmaceutical firm developing targeted contrast agents to improve the capability of MRI as a diagnostic tool for a variety of diseases. Gadofosveset trisodium (formerly MS-325, Vasovistâ„¢, now ABLAVARtâ„¢), is an injectable intravascular contrast agents designed for multiple vascular imaging applications, including peripheral vascular disease and coronary artery disease. EPIX conducted a pivotal Phase III trial for the detection of peripheral vascular disease, as well as a Phase II feasibility trial for coronary artery disease diagnosis.
To ensure rapid development and adoption of gadofosveset trisodium into clinical practice upon regulatory approval, EPIX pursued an aggressive product development plan and commercialization strategy. The Company established an exclusive, worldwide sales and marketing agreement with Bayer Schering Pharma AG. EPIX also established corporate collaborations with GE Healthcare, Philips Medical Systems and Siemens Medical Systems, the three leading MRI manufacturers, which together account for approximately 80 percent of the MRI machines installed worldwide.
EPIX had other MRI contrast agents under development, most significantly a novel prototype blood clot agent (EP-2104R). Potential clinical applications for this type of agent include detection of deep venous thrombosis, pulmonary embolism and blood clots in the coronary and carotid arteries. Currently, there is no high resolution imaging technique to directly visualize blood clots in patients with suspected cardiovascular disease.

Founded in 1969, Elscint is headquartered in Haifa, Israel. Elscint developed advanced computerized imaging systems in Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Nuclear Medicine (NM) and Mammography (MAM) for international markets.
In November 1998, General Electric Medical Systems (GEMS) acquired the Nuclear Medicine and MRI divisions of Elscint, including an unique MRI gradient system concept and technology (twin gradient system).
Elscint Ltd. signs definitive agreement to sell its Nuclear Medicine and Magnetic Resonance Imaging Businesses for $100 Million. Elscint's shareholders approved the sale of its NM, and MRI division to GE (now GE Healthcare). Picker International acquires the Computed Tomography Division of Elscint Ltd. in the same year.

See also Marconi Medical Systems.

Fractional Nex imaging (GE Healthcare term for imaging with a Nex value less than 1) benefits from the conjugate symmetry of the k-space to reduce the number of phase encoding acquisitions. With fractional Nex imaging (similar to partial Fourier or Half Scan), just over half of the data are acquired and the data from the lower part of k-space are used to fill the upper part, without sampling the upper part. Fractional Nex imaging sequences use a number of excitations values between 0.5 and 1. These values are a bit misleading, because the number of phase encoding steps is reduced, and not the NEX.
Fractional Nex imaging reduces the scan time considerable, by preserving the same contrast between the tissues. The effect by acquiring fewer data points is that the signal to noise ratio decreases.

See also acronyms for 'partial averaging//fractional Nex imaging' from different manufacturers.